Literature DB >> 2689685

[Refractory idiopathic thrombocytopenic purpura which responded to protein A column].

T Tauchi, A Suzuki, T Fujimura, H Iwabuchi, J H Ohyashiki, K Ohyashiki, K Toyama, H Nagasawa.   

Abstract

Currently, there is no satisfactory therapy available for patients with chronic idiopathic thrombocytopenic purpura (ITP) who are unresponsive to conventional therapeutic modalities. In this report, we describe a patient with chronic refractory ITP treated with immobilized protein A in an extracorporeal system. The patient was a 74 years old male diagnosed as ITP in 1980. Despite steroid therapy, the disease progressed and the patient exhibited ecchymosis and gum bleeding which was unresponsive to intravenous gammaglobulin therapy. Severe gastrointestinal bleeding was evident and administration of danazol was discontinued due to liver dysfunction. The patient was treated with extracorporeal protein A immunoabsorption. The patient's whole blood (200-300 ml per treatment) was separated into plasma and cellular components and the plasma was passed through an immunoabsorption column containing 200 mg of covalently bound protein A. The treated plasma and cellular components were returned to the patient. After 4 immunoabsorption treatments, the platelet counts elevated and there was evidence of improvement in gastrointestinal bleeding. This report indicates that protein A immunoabsorption therapy should be considered in patients with chronic refractory ITP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689685

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  A 29-year-old woman with persistent thrombocytopenia.

Authors:  Irene Di Pasquale; Antonella Bertomoro; Fabrizio Vianello; Piero Marson; Francesca Boscaro; Fabrizio Fabris
Journal:  Intern Emerg Med       Date:  2019-02-12       Impact factor: 3.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.